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Received December 31, 2014; accepted April 11, 2015AbstractBackground: For patients with an elevated prostate specific antigen (PSA) level or a suspected lesion detected by digital rectal examination,
transrectal ultrasound-guided (TRUS) prostate biopsy is the standard procedure for prostate cancer diagnoses. In Taiwan, TRUS prostate biopsy
has not been well-studied on a nationwide scale. This article aimed to study TRUS prostate biopsy in Taiwan and its related complications,
according to the claims generated through the National Health Insurance (NHI) program.
Methods: We applied for access to claims from the NHI Research Database of Taiwan of all patients who visited the urology clinic during the
period of 2006 to 2010. In the 5-year urology profile, we obtained all records, which included admission and ambulatory clinical records. The
definition of TRUS biopsy included codes for ultrasound-guided procedure and for prostate puncture; other codes involving complications such
as postbiopsy voiding difficulty, significant bleeding, or infection requiring treatment were also included. Risk factors included age, diagnosis of
prostate cancer, hospitalization or nonhospitalization, and the Charlson Comorbidity Index (CCI; with a value of 0, 1, 2 or  3). Descriptive and
comparative analyses were also performed.
Results: In the 5-year urology profile, 12,968 TRUS biopsies performed of which 6885 were in-patient procedures and 6083 were ambulatory
clinic procedures. After the procedures, 1266 (9.76%) biopsies were associated with voiding difficulty; 148 (1.14%) biopsies, with significant
bleeding; and 855 (6.59%) biopsies, with infection that required treatment. The prostate cancer diagnosis rate was 36.02%. The overall biopsy-
related mortality rate within 30 days was 0.25%, and the postbiopsy sepsis-related mortality rate was 0.13%. Age, diagnosis of cancer, hos-
pitalization, and CCI value  1 were all significant factors in univariate analysis and multivariate analysis for postbiopsy voiding difficulty and
severe infection. A diagnosis of cancer and a CCI value  2 were significant factors for significant bleeding after biopsy. Patients diagnosed as
having prostate cancer had fewer bleeding complications after biopsy.
Conclusion: The most frequent complication was postbiopsy voiding difficulty, followed by infection that required treatment and significant
bleeding. The sepsis-related mortality rate was 0.13%. Significant risk factors for postbiopsy complications included age, diagnosis of prostate
cancer, hospitalization, and the CCI value.
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Fig. 1. Age distribution of the patients (representing 12,968 prostatic biopsies).
The mean age is 69.9 years. TRUS ¼ transrectal ultrasound-guided.
Table 1
Clinical data for all 12,968 prostatic biopsies, based on genitourinary service.
Admission (n ¼ 6885) Ambulatory visit (n ¼ 6083)
GU (n ¼ 6457) Not GU (n ¼ 455) GU (n ¼ 6081) Not GU (n ¼ 2)
Malignancy diagnosis 36.0
Postbiopsy 30-d mortality 0.25
Biopsy-related sepsis-induced mortality 0.13
All data are presented as %.
GU ¼ genitourinary department application.
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National Health Insurance (NHI) in Taiwan has been in effect
sinceMay 1995, and the coverage rate is 99%of the population.1
Since 1999, the Bureau of the NHI has established two types of
databases that are subgroups of the larger National Health In-
surance Research Database (NHIRD). One database is the
random sampled database comprising ambulatory visits or
admission datasets; the other database is a special database
generated by requests for selected criteria such as patients
having specific diseases or undergoing specific procedures or
medications. By analyzing the National Health Insurance
Research Database (NHIRD), a nationwide view of specific
clinically significant problems can be scrutinized.
For patients with elevated prostate specific antigen (PSA)
levels or suspected lesion detected by digital rectal examina-
tion, transrectal ultrasound-guided (TRUS) prostate biopsy is
the standard procedure for the diagnosis of prostate cancer.
The incidence and prevalence rate of prostatic disease has
increased because of the phenomenon of an aging population
in Taiwan.2 However, prostate cancer has a variable clinical
course, and a significant proportion of prostate cancer cases
may be indolent cancer. Thus, some patients with prostate
cancer may die with it rather than die of it. There is also a
study that demonstrates that extended biopsy improves the
concordance of the Gleason scores between biopsy and pros-
tatectomy, which indicates it has more complication risks.3
Therefore, whether to check the PSA level in elderly men as
a screening device for cancer has always been subject to
debate, especially when considering complications associated
with TRUS biopsy.4e7 Our investigation aimed to study TRUS
prostate biopsy and related complications in Taiwan, based on
the claims of the NHI program.
2. Methods
From the NHIRD of Taiwan, we applied the data of all
claims of patients who ever visited a urology clinic during the
period of 2006e2010. In the resulting 5-year urology profile,
we received all records from both admission (DO and DD
files) and ambulatory clinics (OO and CD files). Codes for the
ultrasound-guided procedure (19007B or 19002B) and the
prostate puncture (29028C or 79401C) in combination were
used to define TRUS biopsy.
Post-TRUS biopsy complications included voiding diffi-
culty, significant bleeding, or infection requiring treatment.
Postbiopsy voiding difficulty was indicated by an indwelling
catheterization code after biopsy. Postbiopsy significant
bleeding was defined as incidents necessary to be managed
with endoscopic hemostatic procedures or transfusion. Infec-
tion that required treatment was defined by intravenous anti-
biotic administration for at least six dosages, and an admission
period longer than 3 days, either during the admission of the
biopsy or during the first admission within 7 days after biopsy.
The following risk factors were included: age, diagnosis of
prostate cancer (heavy disease verification file, 185), hospi-
talization or nonhospitalization (i.e., biopsy performed eitherthrough admission or ambulatory clinics), and Charlson Co-
morbidity Index value8 (CCI; values are 0, 1, 2, and 3).
Descriptive and comparative analyses were performed
using SPSS version 17.0 software (SPSS Inc., Chicago, IL,
USA). Relative risks were assessed by using Chi square or
logistic regression tests in univariate analysis and multiple
regression for multivariate analysis. This study was approved
and certified by the Institutional Review Board (Taipei Vet-
erans General Hospital, Taipei, Taiwan).
3. Results
In the 5-year urology profile, 12,968 TRUS biopsies were
detected. The mean age of patients at the time of biopsy was
69.9 years (Fig. 1). Among the procedures, 6885 biopsies were
performed during hospitalization and 6083 biopsies were
performed at ambulatory clinics (Table 1); 4671 (36.02%)
patients were diagnosed as having prostate cancer, which was
confirmed by linkage to the heavy disease verification (HV)
file. Thirty-two patients died within 30 days after biopsy
(0.25% biopsy-related mortality); of these, 17 patients had an
infection that required treatment (i.e., 0.13% biopsy-related
sepsis-induced mortality).
Among the 12,968 TRUS prostate biopsies, 1266 (9.76%)
patients had postbiopsy voiding difficulty (Table 2), which
required the use of am indwelling Foley catheter. One hundred
and forty-eight (1.14%) patients who underwent transfusion or
endoscopic management also had significant bleeding (Table
3). Eight hundred and fifty-five (6.59%) patients who
Table 2
Risk factors for voiding difficulty after TRUS biopsies.
Risk factor Voiding difficulty (9.76%)
Univariate
RR
95% CI p Multivariate
RR
95% CI p
Age 1.04 1.03e1.05 <0.001 1.02 1.01e1.03 <0.001
Prostate ca. 1.53 1.37e1.73 <0.001 1.17 1.01e1.34 0.032
Admission 9.01 7.27e11.16 <0.001 5.60 4.78e6.55 <0.001
CCI 1 2.29 1.77e2.97 <0.001 1.38 1.05e1.81 0.020
Admission ¼ admission for TRUS biopsy; CCI ¼ Charlson Comorbidity
Index; CI ¼ confidence interval; admission ¼ admission for TRUS biopsy;
Prostate ca. ¼ prostate cancer diagnosed after TRUS biopsy; RR ¼ relative
risk; TRUS ¼ transrectal ultrasound-guided.
Table 3
Risk factors for significant bleeding after TRUS biopsies.
Risk factor Significant bleeding (1.14%)
Univariate
RR
95% CI p Multivariate
RR
95% CI p
Age 1.02 1.01e1.03 0.015 1.01 0.99e1.03 0.318
Prostate ca. 0.61 0.52e0.83 <0.001 0.67 0.46e0.96 0.028
Admission 2.04 1.43e2.90 <0.001 1.18 0.69e2.02 0.544
CCI 2 2.91 1.82e4.63 <0.001 2.65 1.76e3.85 <0.001
Admission ¼ admission for TRUS biopsy; CCI ¼ Charlson Comorbidity
Index; CI ¼ confidence interval; admission ¼ admission for TRUS biopsy;
Prostate ca. ¼ prostate cancer diagnosed after TRUS biopsy; RR ¼ relative
risk; TRUS ¼ transrectal ultrasound-guided.
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biotics treatment within 7 days after prostate biopsy had an
infection that required treatment (Table 4).
Age, diagnosis of prostate cancer, hospitalization, and a
CCI value of 1 were all significant risk factors for post-
biopsy voiding difficulty and severe infection (Tables 2 and 4)
in univariate and multivariate analyses. For postbiopsy
massive bleeding (Table 3), age and biopsy during admission
were significant factors in univariate analysis. Only a diag-
nosis of cancer and a CCI value of 2 were significant in
univariate analysis and multivariate analysis, and patients
diagnosed with prostate cancer had fewer bleeding compli-
cations after biopsy.
4. Discussion
The undertaking of prostate biopsy via the transrectal route
is the “gold standard” and necessary procedure to diagnoseTable 4
Risk factors for infection requiring treatment after TRUS biopsies.
Risk factor Infection requiring treatment (6.59%)
Univariate
RR
95% CI p Multivariate
RR
95% CI p
Age 1.03 1.02e1.04 <0.001 1.01 1.00e1.02 0.002
Prostate ca. 1.53 1.33e1.76 <0.001 1.03 1.01e1.06 0.025
Admission 2.74 2.20e3.24 <0.001 2.24 1.92e2.60 <0.001
CCI 1 2.22 1.63e3.02 <0.001 1.77 1.29e2.43 <0.001
Admission ¼ admission for TRUS biopsy; CCI ¼ Charlson Comorbidity
Index; CI ¼ confidence interval; admission ¼ admission for TRUS biopsy;
Prostate ca. ¼ prostate cancer diagnosed after TRUS biopsy; RR ¼ relative
risk; TRUS ¼ transrectal ultrasound-guided.prostate cancer. Biopsy-related mortality and morbidity are
important with regard to the high prevalence of prostate cancer
in an older male population.9e12
Based on the nationwide database of NHI in Taiwan, the
postbiopsy sepsis-related mortality rate was 0.13%, which was
higher than the Prostate, Lung, Colorectal, and Ovarian Cancer
Screening (PLCO) trial rate of 0.095%,13 but lower than the
three-country European Randomized Study of Screening for
Prostate Cancer (ERSPCdFinland, The Netherlands, and
Sweden) trial rate of 0.24%.14 However, in the PLCO trial, the
120-day mortality of the nonbiopsy group was 0.18%, and the
multivariate relative risk of biopsy in excess of the control group
was not statistically significant [p ¼ 0.49, 95% confidence in-
terval (CI) ¼ 0.2e1.1].13 The data results in our study lies in
between the results of the other two studies, which implies that
the postbiopsy sepsis ratewould not lead to a greatermortality in
Taiwan than in other countries. In additon, the ERSPC (Finland,
The Netherlands, and Sweden) study14 and PLCO study13
indicate no greater mortality rate after a TRUS biopsy. The
Rotterdam section of ERSPC trial even showed reduced prostate
cancer mortality in a previous study,15 and a corrective study.16
Therefore, the mortality rate after TRUS biopsy is apparently
minimal and not significantly higher, and the TRUS biopsy may
also reduce mortality of individuals who are further diagnosed
with prostate cancer.
In our study, the prostate cancer diagnosis rate was 36%,
which is much higher than the rate in the ERSPC Rotterdam
section (biopsy, 12.8%; nonbiopsy, 6.6%; total, 9.7%)16 and
the Surveillance Epidemiology and End Result study (SEER;
17.1%).17 However, it is only slightly higher than the rate in
the PLCO trial (biopsy, 32.3%).13 However, in an Ontario,
Canada study,7 the prostate cancer diagnosis rate was even
higher at 44.6%. The mean age in each group was 62.4 years
in the ERSPC trial and 63.7 years in the PLCO trialdboth
ages were younger than in our current study. Another single
institutional study in Taiwan revealed that the prostate cancer
diagnosis rate was 23.58% and the individuals' mean age was
67.3 years.18 Therefore, we believe that in Taiwan, TRUS
prostate biopsy is performed in an older population with a
higher cancer detection rate.
We were able to study three major complications after
TRUS prostate biopsiesdvoiding difficulty, significant
bleeding, and infection that required treatment. The rates of
these complications were 9.76%, 1.14%, and 6.59%, respec-
tively. Among the three major complications, infection
requiring treatment accounted for most post-TRUS biopsy
readmissions because voiding difficulty could be managed by
catheterization in an ambulatory clinic or in an emergency
room. Significant bleeding has a smaller occurrence rate. The
SEER study indicates that the 30-day hospitalization rate is
6.9%, which is similar to the rate of 6.59% in our study for
infection that required treatment.17 By contrast, the infection
complication and hospital admission rates in the Rotterdam
section of the ERSPC were 4.2% and 0.8%, respectively.6
However, in the Ontario study, the 30-day hospital admis-
sion rate was 1.4% for all patients.7 For patients with prostate
cancer, the admission rate was 0.8% (which increased from
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cancer, the admission rate was 1.9% (which increased from
1.0% in 1996 to 4.1% in 2005).7 The complication rate trend is
increasing, although it is still lower than the rate in the SEER
trial, the Rotterdam section of ERSPC, and our study. There-
fore, there are concerns that performing more unnecessary
biopsies may result in more complications, especially for men
without prostate cancer in Canada.
In a single institutional study in Taiwan in 2007,18 the rate
of acute urinary retention was 2.1%, which is lower than the
rate in our study at 9.76%; the rate of hematuria plus rectal
bleeding was 1.9 ± 0.2%, which was higher than our signifi-
cant bleeding rate of 1.14%; and the rate of infection-related
complications such as acute prostatitis, epididymitis, and
sepsis was 3.8%, 0.2%, and 0.05%, respectively, which was
apparently lower than our rate of 6.59% for infections
requiring treatment.18 In our study, the increased urinary
retention rate and infection requiring treatment may be the
result of having data associated with a higher average age of
the patients. The difference between our study and the single
institutional study may be attributable to having dissimilar
targeted populations, different definitions of complications,
and altered methodological approaches.
In earlier studies, Chiang et al18 report that only an enlarged
prostate was an associated risk factor for acute prostatitis and
urinary retention. Loeb et al17 report that later year, nonwhite
ethnicity, and higher comorbidity scores were significantly
associated with an increased risk of infection-related compli-
cations in the SEER study, and prostate enlargement and
diabetes were significant risk factors for fever after TRUS
biopsy in the Rotterdam section of the ERSPC trial.6 Pinsky
et al13 suggest that prostate enlargement or inflammation is
significantly associated with a higher rate of infectious and
noninfectious complications, whereas black ethnicity was
associated with infectious complications and repeated biopsy
with noninfectious complications. In summary, an enlarged
prostate, nonwhite ethnicity, and comorbidities such as dia-
betes are associated risk factors for complications after TRUS
biopsy in the literature. Our study revealed that age, diagnosis
of cancer, a CCI value of 1, and biopsy during admission
were the statistically significant risk factors of postbiopsy
voiding difficulty and infection episodes, whereas a diagnosis
of cancer and a CCI value of 2 were associated with sig-
nificant bleeding after a TRUS biopsy.
In conclusion, we studied TRUS prostate biopsy by focusing
on associated complications using a nationwide research data-
base. The most frequently encountered complication of prostate
biopsy was postbiopsy voiding difficulty, followed by infection
requiring treatment, and significant bleeding. Approximately
one in three patients who received TRUS biopsy has been
diagnosed with prostate cancer in Taiwan. Age, diagnosis of
cancer, CCI value  1, and undergoing a biopsy as an inpatient
procedure were significant risk factors of postbiopsy voiding
difficulty and infection episodes; a CCI value 2was correlated
with significant bleeding after TRUS biopsy, whereas diagnosis
of cancer was inversely correlated. The sepsis-related mortality
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